Metabolomic Technologies Receives US Patent Covering Methods of Assessment of Colorectal Cancer and Colorectal Polyps by Measurement of Metabolites in Urine

Share Article

The test, PolypDx, is the first and only urine-based test for the detection and prevention of colorectal cancer

Our innovative new test is a game-changer in the detection and prevention of colorectal cancer.

Metabolomic Technologies Inc. (MTI), an innovative molecular diagnostics company, announced that the US Patent and Trademark Office has issued patent number 10,267,800 as of April 23, 2019. The patent entitled, “Methods for the Assessment of Colorectal Cancer and Colorectal Polyps by Measurement of Metabolites in Urine”, includes fundamental claims describing methods of analyzing a patient’s urine to detect colorectal cancer and precancerous polyps. The patent carries a term extending to 2033. This patent represents the 20th patent that has been granted for MTI’s PolypDx™, the first and only urine test for the detection and prevention of colorectal cancer. Patents have also been issued in Japan, Hong Kong, throughout Europe, Canada and Australia.

“Our innovative new test is a game-changer in the detection and prevention of colorectal cancer”, said Dr. David Chang, Chief Executive Officer for MTI. “We believe this patent acknowledges our unique innovation in colorectal cancer screening and prevention, and importantly, demonstrates our expertise in bringing novel diagnostics from the laboratory to clinically-validated, patient-friendly tests to benefit colorectal cancer screening in the US."

Dr. Chang continued, “We believe that patients and physicians should have access to a full range of test offerings, that, when used appropriately, can increase colorectal cancer screening and ultimately, save lives. We are pleased with the issuance of this patent to strengthen MTI’s intellectual property position and reinforce our leadership in bringing a new, easy-to-use test to patients worldwide.”

About Metabolomic Technologies Inc. (MTI):
MTI is a privately held Canadian company based in Edmonton, Alberta. MTI’s award-winning team is focused on the mission of saving lives through early detection. A spin-off from the University of Alberta, MTI develops metabolomics-based diagnostic systems created from proprietary biomarker technologies. The company received the 2014 Frost & Sullivan Award for Technology Innovation Leadership and the 2017 ASTech Foundation Outstanding Leadership in Technology Award.

About PolypDx™:
PolypDx™ is the first and only urine test for the detection and prevention of colorectal cancer. Clinically validated in two 1000-patient trials in Canada and China, PolypDx™ is a metabolomics-based screening test using Liquid chromatography-mass spectrometry (LC-MS) technology. The test is based on the analysis of key metabolomic biomarkers in urine. PolypDx™ was developed in response to the inadequacies of current colorectal cancer screening methods. With accurate colorectal cancer screening and removal of polyps with colonoscopy, colorectal cancer is completely preventable. However, due to poor performance and low compliance with current screening tests, patients are still developing colorectal cancer or discovering it too late. PolypDx™ is a simple and effective test requiring only a small urine sample and provides healthcare professionals with a new tool in the prevention and detection of colorectal cancer.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jean Forsythe
Visit website